Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLEAN: Fosamprenavir vs Lopinavir in Naive HIV
NCT00085943Phase 3Completed
- Sponsor
- GSK
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of fosamprenavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by GSK. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <400 copies/mL at 48 weeks. Started May 2004; status: completed.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00085943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085943.